SOPHiA GENETICS opts for Nasdaq IPO

SOPHiA Genetics is a pioneer in the digital health sector and one of the fastest growing companies in this vertical. Powered by artificial intelligence (AI), the SOPHiA DDM platform enables users to generate insights across complex genomic and phenotypic datasets providing analysis and insights across multiple disease areas, from oncology to inherited disorders. The platform and related solutions, products and services are currently used by more than 750 hospital, laboratory and biopharma institutions in more than 70 countries.

The company has raised around 230 million francs since its incorporation in 2011. According to estimates, it was valued at around CHF 500 million in the most recent financing round in September 2020. SOPHiA Genetics had been considered an IPO candidate for some time, but it was still unclear which stock exchange would be chosen for the listing. Now the Lausanne-based company which has an office in Boston since 2018 has apparently taken a decision.

SOPHiA has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its ordinary shares. The company has applied to list its ordinary shares on The Nasdaq Global Select Market under the symbol "SOPH." Further details on the IPO, including the target date, were not disclosed.

(SK)